JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fedan, J. S.
Right arrow Articles by Day, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fedan, J. S.
Right arrow Articles by Day, B.

Contraction of the guinea pig isolated, perfused trachea to purine and pyrimidine agonists

JS Fedan, JL Stem and B Day

Physiology Section, National Institute for Occupational Safety and Health, Morgantown, West Virginia.

Unlike methacholine and histamine, ATP and uridine 5'-triphosphate (UTP) are more potent contractile agonists when they are applied to the mucosal (intraluminal, IL) surface of the guinea pig perfused trachea than when they are applied to the serosal (extraluminal, EL) surface. The relative contractile activities of a series of purine and pyrimidine compounds were assessed. The order of EL activity was: [2- methythio ATP (2 MeSATP) = adenosine 5'-diphosphate (ADP)] > [adenosine 5'-O-(2-thiodiphosphate) (ADP beta S) = ATP = adenosine 5'-O-(3- thiotriphosphate) (ATP gamma S)] > [(beta, gamma-imido ATP) (APPNP) = alpha, beta-methylene ATP (APCPP)] > [UTP = uridine 5'-diphosphate (UDP) = inosine 5'-triphosphate (ITP)] > [xanthosine 5'-triphosphate (XTP) beta, gamma-methylene ATP (APPCP)]. EL adenosine, adenosine 5'- monophosphate, uridine 5'-monophosphate and uridine were weak or inactive. The EL order of activity, therefore, shares some characteristics of P2Y receptors. The order of IL activity was: (ATP = UTP = ITP) > (ATP gamma S = ADP = APPNP = 2 MeSATP) > (UDP = ADP beta S = XTP) > APCPP; the other compounds were weak or inactive. The IL order of activity, therefore, resembled that for P2U or "nucleotide receptors." ATP, APPNP, UTP, UDP, ITP and XTP were more active when added to the IL than after administration to the EL bath; the remaining compounds were similarly active EL and IL, or were more active EL than IL. Greater IL than EL activity of agonists was a property associated with preference for P2U-receptors.(ABSTRACT TRUNCATED AT 250 WORDS)

Volume 268, Issue 3, pp. 1321-1327, 03/01/1994
Copyright © 1994 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
V. Govindaraju, J. G. Martin, K. Maghni, P. Ferraro, and M.-C. Michoud
The Effects of Extracellular Purines and Pyrimidines on Human Airway Smooth Muscle Cells
J. Pharmacol. Exp. Ther., November 1, 2005; 315(2): 941 - 948.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
M.-C. Michoud, G. Napolitano, K. Maghni, V. Govindaraju, A. Cogo, and J. G. Martin
Effects of Extracellular Triphosphate Nucleotides and Nucleosides on Airway Smooth Muscle Cell Proliferation
Am. J. Respir. Cell Mol. Biol., December 1, 2002; 27(6): 732 - 738.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
M. C. Michoud, F. C. Tao, A. A. Pradhan, and J. G. Martin
Mechanisms of the Potentiation by Adenosine of Adenosine Triphosphate-Induced Calcium Release in Tracheal Smooth-Muscle Cells
Am. J. Respir. Cell Mol. Biol., July 1, 1999; 21(1): 30 - 36.
[Abstract] [Full Text]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1994 by the American Society for Pharmacology and Experimental Therapeutics.